<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630523</url>
  </required_header>
  <id_info>
    <org_study_id>NL66559.091.18</org_study_id>
    <nct_id>NCT03630523</nct_id>
  </id_info>
  <brief_title>Response of Immune System to Flu Vaccination in PHTS</brief_title>
  <acronym>RIPS</acronym>
  <official_title>Registering the Immune Response to a Flu Vaccination Challenge in PTEN Hamartoma Tumour Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study evaluates the cellular and humoral immune response to seasonal influenze
      vaccination in PTEN Hamartoma Tumor Syndrome. All subjects will be administered flu
      vaccination, half of the subjects will be control subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination inhibition assay titre</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proliferation assay</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin profile</measure>
    <time_frame>21 days, 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>PTEN Hamartoma Tumor Syndrome</condition>
  <arm_group>
    <arm_group_label>Vaccination</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm contains all subjects; vaccination with Influvac Tetra will be administered at start of study, response will be measured in 7 and 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influvac Tetra</intervention_name>
    <description>Tetravalent seasonal flu vaccination 2018/2019</description>
    <arm_group_label>Vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be diagnosed with PHTS based on genetic testing

          -  Must be a Radboudumc patient

          -  Must be 18 years or older

          -  Must be mentally competent

          -  Must have provided written informed consent to participate in the study

          -  Must be able to adhere to visit schedule and available to complete the study

        Exclusion Criteria:

          -  â€¢ Known history of significant medical disorder, which in the investigator's judgment
             might confound the results of the study or pose additional risk to the subject by
             participation in the study

               -  Known hypersensitivity to previous influenza vaccinations (Anaphylaxis)

               -  Must not be allergic to chicken eggwhite

               -  Pregnancy at start of study

               -  Immunocompromised patients and those receiving concomitant immunosuppressive
                  therapy or other immune modulating drugs including chronic steroid treatment.

               -  Bleeding disorders including haemophilia and thrombocytopenia or treatment with
                  anticoagulants(Due to risk of intramuscular hematoma after injection)

               -  Must not have received vaccination with attenuated pathogens in the 4 weeks
                  leading up to study. (Measles, mumps, rubella, yellow fever, rotavirus, BCG,
                  typhoid)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PHTS</keyword>
  <keyword>PTEN</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hamartoma</mesh_term>
    <mesh_term>Hamartoma Syndrome, Multiple</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

